A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers

BACKGROUND: Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, is approved in combination with endocrine therapy or as monotherapy for hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2−) advanced breast cancer outside of China. OBJECTIVE: To evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian, Yang, Nong, Ji, Dongmei, Shen, Weina, Li, Wenhua, Han, Rubing, Wang, Ning, Tao, Haoxun, Chapman, Sonya C., Sykes, Amanda K., Zhang, Wanli, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935732/
https://www.ncbi.nlm.nih.gov/pubmed/33492568
http://dx.doi.org/10.1007/s11523-020-00789-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935732/
https://www.ncbi.nlm.nih.gov/pubmed/33492568
http://dx.doi.org/10.1007/s11523-020-00789-9

Ejemplares similares